title: [The use of prostatilen in treating patients with prostatic diseases].
abstract: A clinical trial of polypeptide prostatic preparation prostatilen has been performed in 37 and 15 patients with chronic prostatitis and prostatic adenoma, respectively. The treatment resulted in attenuation of algetic and dysuria symptoms. Copulative function and spermatogenesis improved. The uroflowmetric index rose, while residual urine and leukocyte count in prostatic secretion reduced. The drug demonstrated antibacterial and immunomodulation effects in the absence of adverse reactions. Prostatilen is indicated in: chronic prostatitis, prostatic adenoma stage I, normospermatogenic and toxic sterility, interoceptive copulative dysfunction, dysuria. The drug in recommended for clinical application.
authors.forename: A F
authors.initials: AF
authors.lastname: Vozianov
authors.forename: I I
authors.initials: II
authors.lastname: Gorpinchenko
authors.forename: N I
authors.initials: NI
authors.lastname: Boĭko
authors.forename: G N
authors.initials: GN
authors.lastname: Drannik
authors.forename: V Kh
authors.initials: VKh
authors.lastname: Khavinson
mesh_terms: D000328:Adult; D000368:Aged; D002908:Chronic Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D011469:Prostatic Diseases / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D012074:Remission Induction; D013076:Sperm Count / Q000187:drug effects
chemical_list: D010455:Peptides; C053892:cytomedins; C069549:prostatilen
vernacular_title: Primenenie prostatilena pri lechenii bol'nykh s zabolevaniiami predstatel'noĭ zhelezy.